Open AccessLong-term treatment with olanzapine in hospital conditions: Prevalence and predictors of the metabolic syndrome
Author(s) -
Iva Popović,
D. Ravanić,
Slobodan Janković,
Drаgаn Мilоvаnоvić,
Marko Folić,
Albina Stanojević,
M. Nenadović,
Milena Ilić
Publication year - 2015
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh1512712p
Subject(s) - medicine , olanzapine , term (time) , metabolic syndrome , pediatrics , intensive care medicine , psychiatry , schizophrenia (object oriented programming) , obesity , physics , quantum mechanics
The risk of metabolic abnormalities is greatly increased in schizophrenic patients started on an atypical antipsychotic medication. Patients with psychiatric disorders exceed mortality ranges resulting from, among others, increased risk of cardiovascular events. Other factors contributing to the development of metabolic syndrome include prolonged duration of illness, increasing age, female sex and lifestyle factors. OBJECTIVE This cross-sectional study was taken up to assess the prevalence of the metabolic syndrome (MetS) in schizophrenic patients receiving olanzapine monotherapy for at least six months and to determine the most important risk factors associated with metabolic syndrome presence in these patients. METHODS A total of 93 long term hospitalized schizophrenic patients (71 men, 22 women), had a screening of the following: case-history data, psychiatric scales, anthropometric measures, blood (fasting glucose, lipid status, C-reactive protein--CRP) and urine samples (microalbuminuria).